esaxerenone esaxerenone esaxerenone (inn) (brand name minnebro; developmental code names cs-3150, xl-550) is a nonsteroidal antimineralocorticoid which was discovered by exelixis and developed by daiichi sankyo company and is approved in japan for the treatment of hypertension. it acts as a highly selective silent antagonist of the mineralocorticoid receptor (mr), the receptor for aldosterone, with greater than 1,000-fold selectivity for this receptor over other steroid hormone receptors, and 4-fold and 76-fold higher affinity for the mr relative to the existing antimineralocorticoids spironolactone and eplerenone. as of january 2019, esaxerenone is in phase iii clinical trials for diabetic nephropathies. esaxerenoneclinical datatrade namesminnebroother namescs-3150; xl-550routes ofadministrationby mouthdrug classantimineralocorticoididentifiers iupac name 1-(2-hydroxyethyl)-4-methyl-n-(4-methylsulfonylphenyl)-5-pyrrole-3-carboxamide cas number1632006-28-0pubchem cid25052023chemspider28666733uniin62tgj04a1keggd10892chemblchembl2181932chemical and physical dataformulac22h21f3n2o4smolar mass466.48 g·mol−13d model (jsmol)interactive image smiles cc1=c(n(c=c1c(=o)nc2=cc=c(c=c2)s(=o)(=o)c)cco)c3=cc=cc=c3c(f)(f)f inchi inchi=1s/c22h21f3n2o4s/c1-14-18(21(29)26-15-7-9-16(10-8-15)32(2,30)31)13-27(11-12-28)20(14)17-5-3-4-6-19(17)22(23,24)25/h3-10,13,28h,11-12h2,1-2h3,(h,26,29)key:nosnhvjanrodgr-uhfffaoysa-n